Related references
Note: Only part of the references are listed.MicroRNA-133a-3p suppresses malignant behavior of non-small cell lung cancer cells by negatively regulating ERBB2
Yanhui Xu et al.
ONCOLOGY LETTERS (2021)
Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis
Amirreza Bitaraf et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2020)
miR-133a-3p Regulates Hepatocellular Carcinoma Progression Through Targeting CORO1C
Shuangxi Han et al.
CANCER MANAGEMENT AND RESEARCH (2020)
SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer
Ming Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
p53 suppression is essential for oncogenic SPAG5 upregulation in lung adenocarcinoma
Tong Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma
Zixi Liang et al.
CELL DEATH & DISEASE (2019)
Methylation-mediated silencing of miR-133a-3p promotes breast cancer cell migration and stemness via miR-133a-3p/MAML1/DNMT3A positive feedback loop
Wanyue Shi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
miR-133a-3p suppresses cell proliferation, migration, and invasion and promotes apoptosis in esophageal squamous cell carcinoma
Yanwei Yin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling
Yubo Tang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma
Yu-Feng Yang et al.
MOLECULAR CANCER (2018)
MicroRNA epigenetic signatures in human disease
Klara Piletic et al.
ARCHIVES OF TOXICOLOGY (2016)
miR-133a enhances the sensitivity of Hep-2 cells and vincristine-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression
Xurui Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
miR-539 inhibits prostate cancer progression by directly targeting SPAG5
Hongtuan Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis
Tarek M. A. Abdel-Fatah et al.
LANCET ONCOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells
Xiaojun Ge et al.
MOLECULAR MEDICINE REPORTS (2015)
MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2
Yuan Yuan et al.
PLOS ONE (2015)
MicroRNA biogenesis pathways in cancer
Shuibin Lin et al.
NATURE REVIEWS CANCER (2015)
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124
Yi Gao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET
Jian-Ya Zhou et al.
CANCER LETTERS (2014)
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
J. Remon et al.
CANCER TREATMENT REVIEWS (2014)
MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Qiong Wu et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway
L-J Yuan et al.
CELL DEATH & DISEASE (2014)
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Howard A. Burris
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Non-Small-Cell Lung Cancers
Kazuhiko Shien et al.
CLINICAL LUNG CANCER (2012)
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non-Small-Cell Lung Cancer
Vassiliki Papadimitrakopoulou
JOURNAL OF THORACIC ONCOLOGY (2012)
starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data
Jian-Hua Yang et al.
NUCLEIC ACIDS RESEARCH (2011)
Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations
Chizuko Yamamoto et al.
CANCER RESEARCH (2010)
Astrin is required for the maintenance of sister chromatid cohesion and centrosome integrity
Kerstin H. Thein et al.
JOURNAL OF CELL BIOLOGY (2007)
MicroRNA signatures in human cancers
George A. Calin et al.
NATURE REVIEWS CANCER (2006)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
Timeline - Gefitinib - a novel targeted approach to treating cancer
RS Herbst et al.
NATURE REVIEWS CANCER (2004)
Review of epidermal growth factor receptor biology
RS Herbst
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Cloning and characterization of hMAP126, a new member of mitotic spindle-associated proteins
MS Chang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Share Paper
